12 Health Care Stocks Moving In Thursday’s Pre-Market Session
Gainers Cosmos Holdings (NASDAQ:COSM) stock rose 45.1% to $0.48 during Thursday’s pre-market session. The company’s market cap stands…
Barclays Maintains Overweight on Solid Biosciences, Raises Price Target to $8
Barclays analyst Gena Wang maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and raises the price target from $2 to $8.
SVB Leerink Maintains Market Perform on Solid Biosciences, Raises Price Target to $6
SVB Leerink analyst Joseph Schwartz maintains Solid Biosciences (NASDAQ:SLDB) with a Market Perform and raises the price target from $1 to $6.
JP Morgan Upgrades Solid Biosciences to Neutral
JP Morgan analyst Anupam Rama upgrades Solid Biosciences (NASDAQ:SLDB) from Underweight to Neutral.
Solid Biosciences Announces Acquisition Of AavantiBio And Concurrent $75M Private Placement
- Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases, led by industry veteran and current AavantiBio CEO, Bo Cumbo -
- Strong synergies expected by
12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers
Pulmatrix (NASDAQ:PULM) shares rose 11.9% to $4.3 during Wednesday's after-market session. The company's market cap stands at $14.5 million.
What 4 Analyst Ratings Have To Say About Solid Biosciences
Over the past 3 months, 4 analysts have published their opinion on Solid Biosciences (NASDAQ:SLDB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.